All In MedTech

Device Trial Radar · NCT06713239

A Randomized Comparison of Personalized Therapy Mgmt Based On Coronary Atherosclerotic Plaque Vs. Usual Care for Symptomatic Patients With Suspicion of CAD

A Randomized Comparison of Personalized Management for Medical and Interventional Therapy Based On Coronary Atherosclerotic Plaque Versus Usual Care for Symptomatic Patients With Suspicion of CAD

Last checked: Nov 19, 2026Latest source record: Jun 5, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingRandomized with 1,000 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

1,000

Planned (sponsor's estimate)

Start

Dec 18, 2024

Primary completion

Dec 2026

Study completion Dec 2026

Sponsor

Lead sponsor
Cleerly, Inc.Not on our public-company list
Sponsor type
Industry
First posted
Dec 3, 2024

More device trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable (typical for device studies)
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Diagnostic
FDA-regulated device
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

PARAMOUNT is a prospective randomized open-label trial testing the hypothesis that a personalized management strategy in symptomatic patients with suspicion of coronary artery disease (CAD), using a CT-based coronary atherosclerotic plaque assessment by AI-enabled quantitative software improves: certainty for diagnosis of CAD, control of CAD risk factors and efficiency of ICA referral with appropriate PCI compared to the usual care strategy based on current AHA/ACC guidelines for care of symptomatic patients with suspicion of CAD.

Conditions

  • Coronary Artery Disease

Interventions

  • Cleerly Labs and Cleerly ISCHEMIADevice

    Participants in the coronary plaque-based care arm will have CCTA at baseline. CCTA images will be redacted and uploaded to Cleerly, interpreted using Cleerly Labs and Cleerly ISCHEMIA, and archived.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. The primary objective of this study is to determine whether a management strategy improves efficiency and effectiveness.Time frame: Through study completion- an average of 1 year
  2. The primary objective of this study is to determine whether a management strategy improves efficiency and effectiveness.Time frame: Through study completion- an average of 1 year
  3. The primary objective of this study is to determine whether a management strategy improves efficiency and effectiveness.Time frame: Through study completion- an average of 1 year

1 more outcomes with a free account

Locations

21 sites in 1 country. Site status is shown where the registry gives one.

  • Cardiology Associates of Mobile

    Mobile, Alabama

  • Valiance Clinical Research- Huntington Park

    Huntington Park, California

  • Cardiovascular Institute of San Diego

    San Diego, California

18 more study sites with a free account

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.